Why is everybody so focused on the coronavirus vaccine instead of looking at the company's entire portfolio? MRNA has so many products that are ready to launch either now or in the next five years. I don't understand how can investors miss such obvious growth potential. I am taking advantage of this, that's for sure.
There are no replies in this thread yet. Be the first to post a reply below: